Base de dados : MEDLINE
Pesquisa : D03.132.098.038.290 [Categoria DeCS]
Referências encontradas : 8590 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 859 ir para página                         

  1 / 8590 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28468476
[Au] Autor:Ezat B; Pihlstrøm L; Aasly J; Tysnes OB; Egge A; Dietrichs E
[Ad] Endereço:Nevrologisk avdeling Oslo universitetssykehus og Det medisinske fakultet Universitetet i Oslo.
[Ti] Título:Use of advanced therapies for Parkinson's disease in Norway.
[Ti] Título:Bruk av avansert behandling ved Parkinsons sykdom i Norge..
[So] Source:Tidsskr Nor Laegeforen;137(9):619-623, 2017 05.
[Is] ISSN:0807-7096
[Cp] País de publicação:Norway
[La] Idioma:eng; nor
[Ab] Resumo:BACKGROUND: Many patients with Parkinson's disease with severe motor fluctuations benefit from advanced therapies ­ either deep brain stimulation or continuous infusion therapy with levodopa-carbidopa intestinal gel or apomorphine. In Norway, deep brain stimulation is provided as a shared national or multi-regional service. The treatment is currently available at Oslo University Hospital and St. Olavs Hospital; prior to 2012 it was also available at Haukeland University Hospital. Infusion therapy has no similar geographical restrictions. We therefore wished to examine geographical differences in the use of the two most common forms of advanced therapy for Parkinson's disease. MATERIAL AND METHOD: The county of residence of all patients receiving deep brain stimulation or infusion therapy with levodopa-carbidopa intestinal gel in the period 2009 ­ 2013 was recorded using data from hospital episode statistics and the Norwegian Prescription Database, respectively. RESULTS: A total of 262 patients with Parkinson's disease began advanced therapy, 146 with deep brain stimulation and 116 with levodopa-carbidopa infusion. Four counties differed significantly from the others in their use of the two methods. Møre og Romsdal, Nordland and Sør-Trøndelag treated a significantly greater proportion of patients with deep brain stimulation, while Rogaland treated a significantly greater proportion with levodopa-carbidopa infusion therapy. INTERPRETATION: Advanced therapies for Parkinson's disease are offered throughout Norway, but there are significant geographical differences in the type of therapy initiated. One possible explanation is that patients in different counties receive different information about the therapeutic options available.
[Mh] Termos MeSH primário: Antiparkinsonianos
Estimulação Encefálica Profunda/estatística & dados numéricos
Uso de Medicamentos
Disparidades em Assistência à Saúde
Doença de Parkinson
[Mh] Termos MeSH secundário: Antiparkinsonianos/administração & dosagem
Antiparkinsonianos/uso terapêutico
Apomorfina/administração & dosagem
Apomorfina/uso terapêutico
Carbidopa/administração & dosagem
Carbidopa/uso terapêutico
Combinação de Medicamentos
Géis
Seres Humanos
Infusões Parenterais
Levodopa/administração & dosagem
Levodopa/uso terapêutico
Noruega/epidemiologia
Doença de Parkinson/tratamento farmacológico
Doença de Parkinson/epidemiologia
Doença de Parkinson/terapia
Educação de Pacientes como Assunto/normas
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antiparkinson Agents); 0 (Drug Combinations); 0 (Gels); 0 (carbidopa, levodopa drug combination); 46627O600J (Levodopa); MNX7R8C5VO (Carbidopa); N21FAR7B4S (Apomorphine)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171219
[Lr] Data última revisão:
171219
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170505
[St] Status:MEDLINE
[do] DOI:10.4045/tidsskr.16.0711


  2 / 8590 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28465234
[Au] Autor:Jung YS; Lee SO
[Ad] Endereço:Department of Food Science and Technology, Keimyung University, Daegu 42601, Republic of Korea.
[Ti] Título:Apomorphine suppresses TNF-α-induced MMP-9 expression and cell invasion through inhibition of ERK/AP-1 signaling pathway in MCF-7 cells.
[So] Source:Biochem Biophys Res Commun;487(4):903-909, 2017 06 10.
[Is] ISSN:1090-2104
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Recent studies have shown that dopamine plays an important role in several types of cancer by inhibiting cell growth and invasion via dopamine receptors (DRs), such as dopamine receptor D2. However, the roles of DR agonists in cancer cell growth and invasion remain unclear. In our study, we found that apomorphine (APO), one of the most commonly prescribed DR agonists, inhibited TNF-α-induced matrix metalloprotease-9 (MMP-9) expression and cell invasion in MCF-7 human breast carcinoma cells through DR-independent pathways. Further mechanistic studies demonstrated that APO suppresses TNF-α-induced transcription of MMP-9 by inhibiting activator protein-1 (AP-1), a well-described transcription factor. This is achieved via extracellular signal-regulated kinases 1 and 2 (ERK1/2). Our study has demonstrated that APO targets human MMP-9 in a DR-independent fashion in MCF-7 cells, suggesting that APO is a potential anticancer agent that can suppress the metastatic progression of cancer cells.
[Mh] Termos MeSH primário: Apomorfina/farmacologia
Movimento Celular/efeitos dos fármacos
MAP Quinases Reguladas por Sinal Extracelular/antagonistas & inibidores
Metaloproteinase 9 da Matriz/genética
Transdução de Sinais/efeitos dos fármacos
Fator de Transcrição AP-1/antagonistas & inibidores
Fator de Necrose Tumoral alfa/antagonistas & inibidores
[Mh] Termos MeSH secundário: Apomorfina/química
Sobrevivência Celular/efeitos dos fármacos
MAP Quinases Reguladas por Sinal Extracelular/metabolismo
Seres Humanos
Células MCF-7
Metaloproteinase 9 da Matriz/metabolismo
Invasividade Neoplásica/prevenção & controle
Receptores Dopaminérgicos/metabolismo
Fator de Transcrição AP-1/metabolismo
Fator de Necrose Tumoral alfa/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Receptors, Dopamine); 0 (Transcription Factor AP-1); 0 (Tumor Necrosis Factor-alpha); EC 2.7.11.24 (Extracellular Signal-Regulated MAP Kinases); EC 3.4.24.35 (Matrix Metalloproteinase 9); N21FAR7B4S (Apomorphine)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171128
[Lr] Data última revisão:
171128
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170504
[St] Status:MEDLINE


  3 / 8590 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28893517
[Au] Autor:Kühn J; Haumesser JK; Beck MH; Altschüler J; Kühn AA; Nikulin VV; van Riesen C
[Ad] Endereço:Charité University Medicine Berlin, Department of Neurology, Berlin, Germany.
[Ti] Título:Differential effects of levodopa and apomorphine on neuronal population oscillations in the cortico-basal ganglia loop circuit in vivo in experimental parkinsonism.
[So] Source:Exp Neurol;298(Pt A):122-133, 2017 Dec.
[Is] ISSN:1090-2430
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The current pharmacotherapy of Parkinson's disease (PD) is primarily based on two classes of drugs: dopamine precursors, namely levodopa, and dopamine receptor agonists, such as apomorphine. Although both types of agents exert their beneficial clinical effects on motor and non-motor symptoms in PD via dopamine receptors, clinical efficiency and side effects differ substantially between levodopa and apomorphine. Levodopa can provide a greater symptomatic relief than dopamine receptor agonists. However, because long-term levodopa use is associated with early debilitating motor fluctuations, dopamine receptor agonists are often recommended in younger patients. The pharmacodynamic basis of these profound differences is incompletely understood. It has been hypothesized that levodopa and dopamine receptor agonists may have diverging effects on beta and gamma oscillations that have been shown to be of importance for the pathophysiology of PD. Here, we used electrophysiological recordings in anesthetized dopamine-intact and dopamine-depleted rats to systemically compare the impact of levodopa or apomorphine on neuronal population oscillations in three nodes of the cortico-basal ganglia loop circuit. Our results showed that levodopa had a higher potency than apomorphine to suppress the abnormal beta oscillations often associated with bradykinesia while simultaneously enhancing the gamma oscillations often associated with increased movement. Our data suggests that the higher clinical efficacy of levodopa as well as some of its side effects, as e.g. dyskinesias may be based on its characteristic ability to modulate beta-/gamma-oscillation dynamics in the cortico-basal ganglia loop circuit.
[Mh] Termos MeSH primário: Apomorfina/uso terapêutico
Gânglios da Base/efeitos dos fármacos
Córtex Cerebral/efeitos dos fármacos
Levodopa/uso terapêutico
Rede Nervosa/efeitos dos fármacos
Transtornos Parkinsonianos/tratamento farmacológico
[Mh] Termos MeSH secundário: Animais
Apomorfina/farmacologia
Gânglios da Base/fisiologia
Córtex Cerebral/fisiologia
Relação Dose-Resposta a Droga
Levodopa/farmacologia
Masculino
Rede Nervosa/fisiologia
Neurônios/efeitos dos fármacos
Neurônios/fisiologia
Transtornos Parkinsonianos/fisiopatologia
Ratos
Ratos Wistar
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
46627O600J (Levodopa); N21FAR7B4S (Apomorphine)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171106
[Lr] Data última revisão:
171106
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170913
[St] Status:MEDLINE


  4 / 8590 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28784133
[Au] Autor:Amoateng P; Adjei S; Osei-Safo D; Kukuia KKE; Bekoe EO; Karikari TK; Kombian SB
[Ad] Endereço:Department of Pharmacology and Toxicology, School of Pharmacy, College of Health Sciences, University of Ghana, P.O Box LG 43, Legon, Accra, Ghana. pamoateng@ug.edu.gh.
[Ti] Título:Extract of Synedrella nodiflora (L) Gaertn exhibits antipsychotic properties in murine models of psychosis.
[So] Source:BMC Complement Altern Med;17(1):389, 2017 Aug 07.
[Is] ISSN:1472-6882
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The hydro-ethanolic whole plant extract of Synedrella nodiflora (SNE) has demonstrated anticonvulsant, sedative and analgesic effects. Preliminary studies conducted in animals, SNE significantly decreased stereotypic behaviours suggesting antipsychotic potential. Coupled with the central nervous system depressant effects of SNE, we hypothesized that it may have utility in the management of psychosis. The present study therefore investigated the antipsychotic potential of the SNE in several murine models of psychosis. METHOD: The primary central nervous system activities of SNE (30-3000 mg/kg, p.o) were investigated using the Irwin's test. The novelty-induced rearing, locomotion and stereotypy counts provoked by SNE (100-1000 mg/kg, p.o) were conducted using the open-field paradigm. The antipsychotic test models used in the screening of SNE (100-1000 mg/kg, p.o) included apomorphine-induced stereotypy, rearing, locomotion and cage climbing activities. The combined effects of a low dose of SNE (100 mg/kg) with various doses of haloperidol and chlorpromazine were analysed using the apomorphine-induced cage climbing and stereotypy, respectively. The ability of SNE to cause catalepsy in naïve mice as well as its effect on haloperidol-induced catalepsy was assessed. RESULTS: SNE showed acetylcholine-like and serotonin-like activities in the Irwin test, with sedation occurring at high doses. SNE significantly reduced the frequencies of novelty- and apomorphine-induced rearing and locomotion; stereotypy behaviour and the frequency and duration of apomorphine-induced cage climbing in mice. In all the tests performed, SNE was less potent than the reference drugs used (chlorpromazine and haloperidol). In addition, SNE potentiated the effects of haloperidol and chlorpromazine on apomorphine-induced cage climbing and stereotypy activities in mice. CONCLUSION: SNE, while exhibiting antipsychotic properties itself, can also potentiate the antipsychotic effects of chlorpromazine and haloperidol.
[Mh] Termos MeSH primário: Antipsicóticos/uso terapêutico
Asteraceae
Atividade Motora/efeitos dos fármacos
Fitoterapia
Extratos Vegetais/uso terapêutico
Transtornos Psicóticos/tratamento farmacológico
[Mh] Termos MeSH secundário: Animais
Antipsicóticos/farmacologia
Apomorfina
Comportamento Animal/efeitos dos fármacos
Catalepsia
Clorpromazina/farmacologia
Clorpromazina/uso terapêutico
Modelos Animais de Doenças
Haloperidol/farmacologia
Haloperidol/uso terapêutico
Interações Ervas-Drogas
Hipnóticos e Sedativos/farmacologia
Hipnóticos e Sedativos/uso terapêutico
Camundongos Endogâmicos BALB C
Camundongos Endogâmicos ICR
Extratos Vegetais/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antipsychotic Agents); 0 (Hypnotics and Sedatives); 0 (Plant Extracts); J6292F8L3D (Haloperidol); N21FAR7B4S (Apomorphine); U42B7VYA4P (Chlorpromazine)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170901
[Lr] Data última revisão:
170901
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170809
[St] Status:MEDLINE
[do] DOI:10.1186/s12906-017-1901-2


  5 / 8590 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28445715
[Au] Autor:Alam M; Rumpel R; Jin X; von Wrangel C; Tschirner SK; Krauss JK; Grothe C; Ratzka A; Schwabe K
[Ad] Endereço:Department of Neurosurgery, Hannover Medical School, Hannover, Germany. Electronic address: Alam.Mesbah@mh-hannover.de.
[Ti] Título:Altered somatosensory cortex neuronal activity in a rat model of Parkinson's disease and levodopa-induced dyskinesias.
[So] Source:Exp Neurol;294:19-31, 2017 Aug.
[Is] ISSN:1090-2430
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Several findings support the concept that sensorimotor integration is disturbed in Parkinson's disease (PD) and in levodopa-induced dyskinesias. In this study, we explored the neuronal firing activity of excitatory pyramidal cells and inhibitory interneurons in the forelimb region of the primary somatosensory cortex (S1FL-Ctx), along with its interaction with oscillatory activity of the primary motor cortex (MCtx) in 6-hydroxydopamine lesioned hemiparkinsonian (HP) and levodopa-primed dyskinetic (HP-LID) rats as compared to controls under urethane (1.4g/kg, i.p.) anesthesia. Further, gene expression patterns of distinct markers for inhibitory GABAergic neurons were analyzed in both cortical regions. While firing frequency and burst activity of S1FL-Ctx inhibitory interneurons were reduced in HP and HP-LID rats, measures of irregularity were enhanced in pyramidal cells. Further, enhanced coherence of distinct frequency bands of the theta/alpha, high-beta, and gamma frequency, together with enhanced synchronization of putative pyramidal cells and interneurons with MCtx oscillatory activity were observed. While GABA level was similar, gene expression levels of interneuron and GABAergic markers in S1FL-Ctx and MCtx of HP-LID rats differed to some extent. Our study shows that in a rat model of PD with dyskinesias, neuronal activity in putative interneurons was reduced, which was accompanied by high beta and gamma coherence between S1FL-Ctx and MCtx, together with changes in gene expression, indicating maladaptive neuroplasticity after long term levodopa treatment.
[Mh] Termos MeSH primário: Potenciais de Ação/fisiologia
Discinesia Induzida por Medicamentos/patologia
Córtex Motor/patologia
Neurônios/fisiologia
Doença de Parkinson Secundária/patologia
[Mh] Termos MeSH secundário: Potenciais de Ação/efeitos dos fármacos
Animais
Antiparkinsonianos/efeitos adversos
Apomorfina/farmacologia
Modelos Animais de Doenças
Feminino
Glutamato Descarboxilase/metabolismo
Levodopa/efeitos adversos
Proteínas do Tecido Nervoso/genética
Proteínas do Tecido Nervoso/metabolismo
Neurônios/efeitos dos fármacos
Oxidopamina/toxicidade
Doença de Parkinson Secundária/induzido quimicamente
Doença de Parkinson Secundária/tratamento farmacológico
RNA Mensageiro/metabolismo
Ratos
Ratos Sprague-Dawley
Receptores de GABA/genética
Receptores de GABA/metabolismo
Simpatolíticos/toxicidade
Espectrometria de Massas em Tandem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antiparkinson Agents); 0 (Nerve Tissue Proteins); 0 (RNA, Messenger); 0 (Receptors, GABA); 0 (Sympatholytics); 46627O600J (Levodopa); 8HW4YBZ748 (Oxidopamine); EC 4.1.1.15 (Glutamate Decarboxylase); EC 4.1.1.15 (glutamate decarboxylase 1); N21FAR7B4S (Apomorphine)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170427
[St] Status:MEDLINE


  6 / 8590 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28400230
[Au] Autor:Ishiba H; Noguchi T; Shu K; Ohno H; Honda K; Kondoh Y; Osada H; Fujii N; Oishi S
[Ad] Endereço:Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan.
[Ti] Título:Investigation of the inhibitory mechanism of apomorphine against MDM2-p53 interaction.
[So] Source:Bioorg Med Chem Lett;27(11):2571-2574, 2017 06 01.
[Is] ISSN:1464-3405
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Mirror-image screening using d-proteins is a powerful approach to provide mirror-image structures of chiral natural products for drug screening. During the course of our screening study for novel MDM2-p53 interaction inhibitors, we identified that NPD6878 (R-(-)-apomorphine) inhibited both the native l-MDM2-l-p53 interaction and the mirror-image d-MDM2-d-p53 interaction at equipotent doses. In addition, both enantiomers of apomorphine showed potent inhibitory activity against the native MDM2-p53 interaction. In this study, we investigated the inhibitory mechanism of both enantiomers of apomorphine against the MDM2-p53 interaction. Achiral oxoapomorphine, which was converted from chiral apomorphines under aerobic conditions, served as the reactive species to form a covalent bond at Cys77 of MDM2, leading to the inhibitory effect against the binding to p53.
[Mh] Termos MeSH primário: Apomorfina/metabolismo
Proteínas Proto-Oncogênicas c-mdm2/metabolismo
Proteína Supressora de Tumor p53/metabolismo
[Mh] Termos MeSH secundário: Apomorfina/química
Linhagem Celular Tumoral
Seres Humanos
Ligação Proteica
Proteínas Proto-Oncogênicas c-mdm2/antagonistas & inibidores
Estereoisomerismo
Relação Estrutura-Atividade
Ressonância de Plasmônio de Superfície
Proteína Supressora de Tumor p53/antagonistas & inibidores
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Tumor Suppressor Protein p53); EC 2.3.2.27 (Proto-Oncogene Proteins c-mdm2); N21FAR7B4S (Apomorphine)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:171124
[Lr] Data última revisão:
171124
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170413
[St] Status:MEDLINE


  7 / 8590 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28392213
[Au] Autor:Santos BG; Carey RJ; Carrera MP
[Ad] Endereço:Behavioral Pharmacology Group, Laboratory of Morphology and Pathology Animal Health, State University of North Fluminense Darcy Ribeiro, Avenida Alberto Lamego, 2000, Campos dos Goytacazes 28013-600, RJ, Brazil.
[Ti] Título:The acquisition, extinction and spontaneous recovery of Pavlovian drug conditioning induced by post-trial dopaminergic stimulation/inhibition.
[So] Source:Pharmacol Biochem Behav;156:24-29, 2017 May.
[Is] ISSN:1873-5177
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:In contextual drug conditioning, the onset of the drug treatment is contiguous with the contextual cues. Evidence suggests that drug conditioning also can occur if there is a discontinuity between the onset of the drug effect and offset of the contextual cues. Here we examine whether post-trial contextual drug conditioning conforms to several Pavlovian conditioning tenets namely: acquisition, extinction and spontaneous recovery. Six groups of rats received apomorphine (0.05 or 2.0mg/kg) and vehicle immediately or after a 15min delay following a 5min non-drug exposure to an open-field during three successive days (conditioning phase). The extinction phase occurred on days 4-8, in which all post-trial treatments were vehicle injections. After 2days of non-testing, the final test was performed. The results showed that on the first test day, the activity levels of the 6 groups were statistically equivalent. On test day 2, there were marked differences in activity levels selectively between the two immediate post-trial apomorphine treatment groups. The immediate low dose apomorphine group displayed a reduction in activity and the immediate high dose group an increase in activity relative to their day 1 levels. The activity levels of both vehicle groups and both apomorphine delay groups remained equivalent to their day 1 activity levels. On test day 3, the differences in activity levels between the two immediate post-trial apomorphine groups increased but the activity levels of the vehicle groups and the 15min delay post-trial apomorphine groups remained unchanged. In the extinction phase, the conditioned activity differences between the two immediate post-trial apomorphine groups were gradually eliminated. During the final test, the activity differences between the immediate post-trial apomorphine groups were partially restored, indicative of spontaneous recovery. These findings are consistent with several basic elements of Pavlovian conditioning and are supportive of drug induced trace conditioning.
[Mh] Termos MeSH primário: Apomorfina/farmacologia
Condicionamento Clássico/efeitos dos fármacos
Dopamina/farmacologia
[Mh] Termos MeSH secundário: Animais
Masculino
Ratos
Ratos Wistar
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
N21FAR7B4S (Apomorphine); VTD58H1Z2X (Dopamine)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171109
[Lr] Data última revisão:
171109
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170411
[St] Status:MEDLINE


  8 / 8590 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28294334
[Au] Autor:Becker G; Bahri MA; Michel A; Hustadt F; Garraux G; Luxen A; Lemaire C; Plenevaux A
[Ad] Endereço:GIGA - CRC In vivo Imaging, University of Liège, Liège, Belgium.
[Ti] Título:Comparative assessment of 6-[ F]fluoro-L-m-tyrosine and 6-[ F]fluoro-L-dopa to evaluate dopaminergic presynaptic integrity in a Parkinson's disease rat model.
[So] Source:J Neurochem;141(4):626-635, 2017 May.
[Is] ISSN:1471-4159
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Because of the progressive loss of nigro-striatal dopaminergic terminals in Parkinson's disease (PD), in vivo quantitative imaging of dopamine (DA) containing neurons in animal models of PD is of critical importance in the preclinical evaluation of highly awaited disease-modifying therapies. Among existing methods, the high sensitivity of positron emission tomography (PET) is attractive to achieve that goal. The aim of this study was to perform a quantitative comparison of brain images obtained in 6-hydroxydopamine (6-OHDA) lesioned rats using two dopaminergic PET radiotracers, namely [ F]fluoro-3,4-dihydroxyphenyl-L-alanine ([ F]FDOPA) and 6-[ F]fluoro-L-m-tyrosine ([ F]FMT). Because the imaging signal is theoretically less contaminated by metabolites, we hypothesized that the latter would show stronger relationship with behavioural and post-mortem measures of striatal dopaminergic deficiency. We used a within-subject design to measure striatal [ F]FMT and [ F]FDOPA uptake in eight partially lesioned, eight fully lesioned and ten sham-treated rats. Animals were pretreated with an L-aromatic amino acid decarboxylase inhibitor. A catechol-O-methyl transferase inhibitor was also given before [ F]FDOPA PET. Quantitative estimates of striatal uptake were computed using conventional graphical Patlak method. Striatal dopaminergic deficiencies were measured with apomorphine-induced rotations and post-mortem striatal DA content. We observed a strong relationship between [ F]FMT and [ F]FDOPA estimates of decreased uptake in the denervated striatum using the tissue-derived uptake rate constant K . However, only [ F]FMT K succeeded to discriminate between the partial and the full 6-OHDA lesion and correlated well with the post-mortem striatal DA content. This study indicates that the [ F]FMT could be more sensitive, with respect of [ F]FDOPA, to investigate DA terminals loss in 6-OHDA rats, and open the way to in vivo L-aromatic amino acid decarboxylase activity targeting in future investigations on progressive PD models.
[Mh] Termos MeSH primário: Di-Hidroxifenilalanina/análogos & derivados
Doença de Parkinson Secundária/diagnóstico por imagem
Doença de Parkinson/diagnóstico por imagem
Compostos Radiofarmacêuticos
Receptores Pré-Sinápticos/metabolismo
Tirosina/análogos & derivados
[Mh] Termos MeSH secundário: Animais
Apomorfina/farmacologia
Descarboxilases de Aminoácido-L-Aromático/metabolismo
Modelos Animais de Doenças
Dopamina/metabolismo
Radioisótopos de Flúor
Processamento de Imagem Assistida por Computador
Masculino
Neostriado/diagnóstico por imagem
Oxidopamina
Doença de Parkinson Secundária/induzido quimicamente
Tomografia por Emissão de Pósitrons
Ratos
Ratos Sprague-Dawley
Comportamento Estereotipado/efeitos dos fármacos
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Fluorine Radioisotopes); 0 (Radiopharmaceuticals); 0 (Receptors, Presynaptic); 148613-12-1 (6-fluoro-3-tyrosine); 2C598205QX (fluorodopa F 18); 42HK56048U (Tyrosine); 63-84-3 (Dihydroxyphenylalanine); 8HW4YBZ748 (Oxidopamine); EC 4.1.1.28 (Aromatic-L-Amino-Acid Decarboxylases); N21FAR7B4S (Apomorphine); VTD58H1Z2X (Dopamine)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170807
[Lr] Data última revisão:
170807
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170316
[St] Status:MEDLINE
[do] DOI:10.1111/jnc.14016


  9 / 8590 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28279509
[Au] Autor:Defebvre L; Moreau C
[Ad] Endereço:Université de Lille, faculté de médecine, CHRU de Lille, centre expert Parkinson, hôpital Salengro, service de neurologie et pathologie du mouvement, Inserm 1171, 59037 Lille, France. Electronic address: luc.defebvre@chru-lille.fr.
[Ti] Título:[Medical and surgical treatment of Parkinson's disease].
[Ti] Título:Traitements médical et chirurgical de la maladie de Parkinson..
[So] Source:Presse Med;46(2 Pt 1):218-224, 2017 Mar.
[Is] ISSN:2213-0276
[Cp] País de publicação:France
[La] Idioma:fre
[Ab] Resumo:The treatment of Parkinson's disease is symptomatic with the use of dopaminergic medications: levodopa, dopaminergic agonists and enzymatic inhibitors. At the initial stage, the main goals are to improve the quality of life of patients and delay the onset of motor complications, using a combination of these therapies taking into account both clinical disability and tolerance of different treatments. At the stage of motor and non-motor fluctuations inhibitors of MAO-B and COMT are proposed; amantadine may limit moderate dyskinesias. At the stage of disabling fluctuations continuous dopaminergic strategy is discussed: deep brain stimulation of different targets, subcutaneous apomorphine pump and intra intestinal Duodopa administration. The monitoring of side effects remains essential for an early adjustment of medications; mainly nausea, orthostatic hypotension, drowsiness and sleep attacks, dyskinesias and behavioral disorders (hallucinations, impulse control disorders). A care pathway published in 2014 by the HAS develops the management process of parkinsonism and its multidisciplinary outpatient.
[Mh] Termos MeSH primário: Antiparkinsonianos/uso terapêutico
Estimulação Encefálica Profunda
Doença de Parkinson/terapia
[Mh] Termos MeSH secundário: Apomorfina/uso terapêutico
Inibidores das Descarboxilases de Aminoácidos Aromáticos/uso terapêutico
Inibidores de Catecol O-Metiltransferase/uso terapêutico
Terapia Combinada
Estimulação Encefálica Profunda/efeitos adversos
Estimulação Encefálica Profunda/métodos
Progressão da Doença
Agonistas de Dopamina/uso terapêutico
Reação a Corpo Estranho/etiologia
Seres Humanos
Hemorragias Intracranianas/etiologia
Inibidores da Monoaminoxidase/uso terapêutico
Transtornos do Humor/etiologia
Doença de Parkinson/tratamento farmacológico
Seleção de Pacientes
Qualidade de Vida
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antiparkinson Agents); 0 (Aromatic Amino Acid Decarboxylase Inhibitors); 0 (Catechol O-Methyltransferase Inhibitors); 0 (Dopamine Agonists); 0 (Monoamine Oxidase Inhibitors); N21FAR7B4S (Apomorphine)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170406
[Lr] Data última revisão:
170406
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170311
[St] Status:MEDLINE


  10 / 8590 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28157650
[Au] Autor:Maya-López M; Ruiz-Contreras HA; de Jesús Negrete-Ruíz M; Martínez-Sánchez JE; Benítez-Valenzuela J; Colín-González AL; Villeda-Hernández J; Sánchez-Chapul L; Parra-Cid C; Rangel-López E; Santamaría A
[Ad] Endereço:Laboratorio de Aminoácidos Excitadores, Instituto Nacional de Neurología y Neurocirugía, S.S.A., Mexico City, Mexico.
[Ti] Título:URB597 reduces biochemical, behavioral and morphological alterations in two neurotoxic models in rats.
[So] Source:Biomed Pharmacother;88:745-753, 2017 Apr.
[Is] ISSN:1950-6007
[Cp] País de publicação:France
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: URB597 is a compound largely linked to the inhibition of fatty acid amide hydrolase (FAAH), an enzyme responsible for the metabolic degradation of the endocannabinoid anandamide (AEA). Despite this pharmacological property accounts for its modulatory profile demonstrated in some neurotoxic paradigms, the possible protective properties of this agent have been poorly investigated, and deserve exploration in different neurotoxic models. In this study, we explored the effects of URB597 on oxidative damage to lipids and other major endpoints of toxicity in two neurotoxic models in vivo in rats (the first one produced by the mitochondrial neurotoxin 3-nitropropionic acid [3-NP], and the other generated by the striatal injection of the pro-oxidant toxin 6-hydroxidopamine [6-OHDA]) in order to provide further supporting evidence of its modulatory profile. METHODS: Male Wistar adult rats were treated for 5 or 7 consecutive days with URB597 (0.3mg/kg, i.p.) and simultaneously exposed to three injections of 3-NP (30mg/kg, i.p.) or a single intrastriatal infusion of 6-OHDA (0.02mg/2µl), respectively. Twenty four hours after all treatments were administered, lipid peroxidation was measured in the striatum of 3-NP-treated rats, and in the midbrain of 6-OHDA-treated rats. Motor skills and histological assessment in the striatum were also evaluated in 3-NP-treated rats 6 and 7days after the last drug administration, respectively; whereas apomorphine-induced circling behavior and tyrosine hydroxylase immunolocalization in the striatum and substantia nigra were investigated 21 and 22days after the last drug infusion, respectively. RESULTS: URB597 prevented the oxidative damage to lipids induced by 3-NP in the striatum, and this effect could account for the attenuation of motor deficits in this model. Attenuation of motor disturbances induced by URB597 in both models was associated with the morphological preservation of the striatum in the 3-NP model and the partial preservation of tyrosine hydroxylase in the 6-OHDA model in the SNpc and striatum. CONCLUSION: The modulatory actions exerted by URB597 in both toxic models support its potential against toxic conditions implying motor and neurochemical alterations linked to energy depletion, excitotoxicity and oxidative stress. Although most of these effects could be attributable to its action on FAAH and further AEA accumulation, in light of our present findings other properties are suggested.
[Mh] Termos MeSH primário: Benzamidas/uso terapêutico
Carbamatos/uso terapêutico
Fármacos Neuroprotetores/uso terapêutico
Síndromes Neurotóxicas/tratamento farmacológico
[Mh] Termos MeSH secundário: Amidoidrolases/antagonistas & inibidores
Animais
Apomorfina
Comportamento Animal/efeitos dos fármacos
Peso Corporal/efeitos dos fármacos
Injeções
Peroxidação de Lipídeos/efeitos dos fármacos
Masculino
Destreza Motora/efeitos dos fármacos
Neostriado
Síndromes Neurotóxicas/patologia
Síndromes Neurotóxicas/psicologia
Nitrocompostos
Oxidopamina
Propionatos
Ratos
Ratos Wistar
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Benzamides); 0 (Carbamates); 0 (Neuroprotective Agents); 0 (Nitro Compounds); 0 (Propionates); 0 (cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester); 8HW4YBZ748 (Oxidopamine); EC 3.5.- (Amidohydrolases); EC 3.5.1.- (fatty-acid amide hydrolase); N21FAR7B4S (Apomorphine); QY4L0FOX0D (3-nitropropionic acid)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170313
[Lr] Data última revisão:
170313
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170204
[St] Status:MEDLINE



página 1 de 859 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde